舒泰神所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、抗癌治癌、创 新药、仿制药、AI医药等。 截至9月30日，舒泰神股东户数4.65万，较上期增加46.97%；人均流通股9745股，较上期减少31.98%。 2025年1月-9月，舒泰神实现营业收入1.81亿元，同比减少30.82%；归母净利润-3068.95万元，同比减少 227.71%。 分红方面，舒泰神A股上市后累计派现7.71亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，舒泰神十大流通股东中，兴全合润混合A（163406）位居第三大 流通股东，持股1226.91万股，相比上期减少345.19万股。兴全合宜混合A（163417）位居第五大流通股 东，持股933.96万股，相比上期增加338.75万股。易方达医疗保健行业混合A（110023）位居第八大流 通股东，持股583.89万股，持股数量较上期不变。兴全商业模式混合(LOF)A（163415）、兴全新视野 定期开放混合型发起式（001511）、永赢医药创新智选混合发起A（015915）退出十大流通股东之列。 11月14日，舒泰神盘中上涨2.04 ...

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and is focusing on innovative biopharmaceuticals, particularly in the field of therapeutic antibodies [1][2][3]. Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3]. - The company recorded a net profit attributable to shareholders of -551 million yuan, which is a 48.60% increase compared to the previous period [3]. Stock Market Activity - On November 14, 2025, the stock price of Rongchang Biopharmaceuticals fell by 2.04%, trading at 87.18 yuan per share with a market capitalization of 49.135 billion yuan [1]. - The stock has increased by 189.54% year-to-date, with a recent 5-day increase of 0.28% and a 20-day decline of 10.47% [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average circulating shares per person decreased by 15.54% to 10,639 shares [3][4]. - Major shareholders include Hong Kong Central Clearing Limited and Wanjiayouxuan, with notable changes in their holdings [4].

Core Viewpoint - JianKai Technology's stock price has experienced fluctuations, with a year-to-date increase of 54.36% but a recent decline in the last five trading days by 5.13% [2] Group 1: Stock Performance - As of November 13, JianKai Technology's stock price was 87.66 CNY per share, with a market capitalization of 5.317 billion CNY [1] - The stock has seen a net outflow of 4.8918 million CNY in principal funds, with large orders buying 2.3557 million CNY (4.87%) and selling 7.2475 million CNY (14.99%) [1] - Year-to-date, the stock has been on the龙虎榜 once, with a net purchase of 39.1731 million CNY on July 21 [2] Group 2: Financial Performance - For the period from January to September 2025, JianKai Technology reported revenue of 211 million CNY, a year-on-year increase of 13.47%, and a net profit attributable to shareholders of 40.7246 million CNY, up 24.72% [2] - The company has distributed a total of 178 million CNY in dividends since its A-share listing, with 99.8755 million CNY distributed in the last three years [3] Group 3: Company Overview - JianKai Technology, established on October 9, 2001, and listed on August 26, 2020, is located in Beijing and specializes in the research, production, and sales of medical-grade polyethylene glycol and its active derivatives [2] - The company's main revenue sources are product sales (96.79%), technology usage fees (2.91%), and transportation services (0.30%) [2] - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and raw materials, with concepts including anti-cancer drugs and medical devices [2]

资料显示，北京神州细胞生物技术集团股份公司位于北京市北京经济技术开发区科创七街31号院，成立 日期2007年4月23日，上市日期2020年6月22日，公司主营业务涉及恶性肿瘤、自身免疫性疾病、感染性 疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。主营业务收入构成为：销售商品 100.00%。 神州细胞所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：抗癌治癌、创新 药、细胞治疗、抗癌药物、百度概念等。 截至9月30日，神州细胞股东户数1.37万，较上期增加40.96%；人均流通股32390股，较上期减少 29.06%。2025年1月-9月，神州细胞实现营业收入13.12亿元，同比减少32.27%；归母净利润-2.51亿元， 同比减少267.17%。 机构持仓方面，截止2025年9月30日，神州细胞十大流通股东中，香港中央结算有限公司位居第六大流 通股东，持股461.68万股，为新进股东。南方中证500ETF（510500）位居第七大流通股东，持股260.91 万股，相比上期减少9.34万股。创新药（159992）位居第十大流通股东，持股178.93万股，为新进股 东。中欧医疗健康 ...

Core Viewpoint - Nanjing Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 51.38% but a recent decline in the last 60 days by 27.90% [2][3] Company Overview - Nanjing Pharmaceutical, established on December 27, 2006, and listed on March 26, 2020, focuses on the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cardiovascular diseases and diabetes [2] - The company operates entirely in the chemical drug formulation sector, with 100% of its revenue derived from this area [2] Financial Performance - For the period from January to September 2025, Nanjing Pharmaceutical reported a revenue of 83.15 million yuan, a year-on-year decrease of 66.89%, and a net profit attributable to shareholders of -68.63 million yuan, reflecting a 19.96% decline [3] - The company has not distributed any dividends in the last three years, with a total payout of 40.74 million yuan since its A-share listing [4] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 49.13% to 14,100, while the average number of tradable shares per person decreased by 32.95% to 19,441 shares [3] - New institutional shareholders include several funds from GF Fund Management, indicating a shift in the shareholder base [4] Market Activity - Nanjing Pharmaceutical's stock experienced a net outflow of 529,500 yuan in major funds, with significant buying and selling activity observed [1] - The stock has appeared on the "Dragon and Tiger List" seven times this year, indicating notable trading activity [2]

奥赛康今年以来股价涨51.47%，近5个交易日涨0.10%，近20日跌1.60%，近60日跌27.02%。 今年以来奥赛康已经2次登上龙虎榜，最近一次登上龙虎榜为7月16日。 资料显示，北京奥赛康药业股份有限公司位于江苏省南京市江宁科学园科建路699号，成立日期1996年 12月24日，上市日期2015年5月15日，公司主营业务涉及消化类、抗肿瘤类及其他药品的研发、生产和 销售。主营业务收入构成为：抗肿瘤类38.28%，抗感染类24.74%，慢性病类21.65%，消化类12.33%， 其他(补充)2.34%，其他类0.66%。 奥赛康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、创新药、生物 医药、幽门螺杆概念、中盘等。 11月12日，奥赛康盘中上涨2.03%，截至09:53，报19.07元/股，成交5704.65万元，换手率0.33%，总市 值177.00亿元。 资金流向方面，主力资金净流入374.27万元，特大单买入336.85万元，占比5.90%，卖出0.00元，占比 0.00%；大单买入626.91万元，占比10.99%，卖出589.50万元，占比10.33%。 分红方面， ...

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 408.10%, but a recent decline over the past 60 days of 24.47% [1][2] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai Sheng), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported operating revenue of 181 million yuan, a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.69 million yuan, a year-on-year decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%. The average circulating shares per person decreased by 31.98% to 9,745 shares [2] - The top ten circulating shareholders include notable funds such as Xingquan Helun Mixed A and Yifangda Healthcare Industry Mixed A, with changes in their holdings noted [3] Market Activity - On November 12, the stock price rose by 2.00% to 37.65 yuan per share, with a trading volume of 530 million yuan and a turnover rate of 3.17%. The total market capitalization reached 17.988 billion yuan [1] - The stock has appeared on the daily trading list (龙虎榜) eight times this year, with the most recent occurrence on October 31, where it recorded a net purchase of 373 million yuan [1]

Core Viewpoint - The stock of Ailis has shown significant growth this year, with a notable increase in revenue and net profit, indicating strong business performance and investor interest [1][2]. Group 1: Stock Performance - As of November 12, Ailis's stock price increased by 2.02% to 102.57 CNY per share, with a total market capitalization of 46.156 billion CNY [1]. - Year-to-date, Ailis's stock price has risen by 73.55%, with a 1.56% increase over the last five trading days, a 3.47% decrease over the last 20 days, and a 15.16% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Ailis reported a revenue of 3.733 billion CNY, representing a year-on-year growth of 47.35%, and a net profit attributable to shareholders of 1.616 billion CNY, up 52.01% year-on-year [2]. - Cumulatively, Ailis has distributed 653 million CNY in dividends since its A-share listing [3]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, Ailis had 19,100 shareholders, an increase of 46.82% from the previous period, with an average of 23,551 circulating shares per shareholder, down 31.89% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 20.9471 million shares, an increase of 10.5693 million shares from the previous period [3].

Core Viewpoint - Zai Jian Pharmaceutical has shown a significant stock price increase of 59.32% year-to-date, despite recent fluctuations in trading performance [1][2] Company Overview - Zai Jian Pharmaceutical, established on March 18, 2009, and listed on January 23, 2020, is located in Kunshan, Jiangsu Province, and focuses on the research, production, and sales of chemical and biological new drugs [1][2] - The company's main revenue source is pharmaceuticals, accounting for 99.97% of total revenue, with minimal contributions from intermediates and asset leasing [1] Financial Performance - For the period from January to September 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, representing a year-on-year growth of 54.49% [2] - The company recorded a net profit attributable to shareholders of -93.42 million yuan, showing a year-on-year increase of 4.58% [2] Stock Market Activity - As of November 12, Zai Jian Pharmaceutical's stock price was 99.27 yuan per share, with a market capitalization of 26.278 billion yuan [1] - The stock has experienced a trading volume of 50.129 million yuan, with a turnover rate of 0.19% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 187 million yuan on October 31 [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 8,809, with an average of 30,049 circulating shares per person [2] - Notable institutional shareholders include China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A, with varying changes in their holdings [2]

Core Points - The stock price of Baiotai increased by 2.03% on November 12, reaching 26.59 yuan per share, with a total market capitalization of 11.01 billion yuan [1] - Baiotai's stock has risen by 37.20% year-to-date, but has seen a decline of 1.52% over the past 20 days and 14.25% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million yuan, representing a year-on-year growth of 17.57% [2] - The net profit attributable to the parent company was -224 million yuan, showing a year-on-year increase of 38.72% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Baiotai was 9,397, a decrease of 0.89% from the previous period [2] - The average number of circulating shares per shareholder increased by 0.89% to 44,065 shares [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.02 million shares as a new shareholder [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [1] - The company's main business involves the research, development, and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1]